Abacavir, also known as Ziagen, is a medication used to treat HIV. Formally called a nucleoside reverse transcriptase inhibitors (NRTIs), it works by slowing the spread of HIV in the body. According to the Food and Drug Administration (FDA), an increased risk of heart attack (myocardial infarction or MI) has been seen in several observational studies and one randomized controlled trial (RCT) with abacavir. However, an increased risk of heart attack has not been seen in other RCTs and the safety database maintained by the drug manufacturer.
"FDA conducted a meta-analysis of 26 randomized clinical trials that evaluated abacavir. This meta-analysis did not show an increased risk of MI associated with the use of abacavir. FDA will continue to communicate any new safety information to the public as it becomes available."


